Skip to main content
IMVT
NASDAQ Life Sciences

Immunovant Q1 Loss Widens to $153M as IMVT-1402 Spending Ramps; $798M Cash Funds Path to Graves' Disease Launch

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$39.19
Mkt Cap
$8.107B
52W Low
$14.32
52W High
$41.23
52W Position info
174% above low
Off High info
4.9% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

IMVT has more than doubled off its 52-week low of $14.32.

Summary

Immunovant posted a $153.2M net loss for Q1 FY2027, up from $120.6M a year ago, as R&D costs surged for its IMVT-1402 program. Cash of $797.8M is expected to fund operations to a potential Graves' disease launch, but expansion plans could change that outlook.


Key Events · Earnings and Guidance · IMVT

  • Q1 Loss Widens on Higher R&D

    Net loss of $153.2M vs. $120.6M in Q1 FY2026, driven by a $41.4M increase in R&D expenses to $142.6M as IMVT-1402 trials expand.

  • Cash Runway to Graves' Disease Launch

    $797.8M in cash and equivalents as of June 30, 2026, expected to fund operations to potential commercial launch of IMVT-1402 in Graves' disease under current plans.

  • Potential Pipeline Expansion Under Review

    Management is evaluating expanding development plans following positive D2T RA data; updated cash runway guidance will be provided after D2T RA and CLE top-line results in H2 2026.

  • New Manufacturing Commitment

    Entered into a minimum $22.8M contract manufacturing agreement for IMVT-1402 drug substance, with $4.2M due in FY2027 and $18.6M in FY2028.


Analysis · IMVT · Life Sciences

Immunovant's quarterly loss grew to $153.2 million from $120.6 million a year ago, driven by a 41% jump in R&D spending as the company advances its lead asset IMVT-1402 across six indications. The balance sheet remains strong with $797.8 million in cash, which management says is enough to reach a potential commercial launch in Graves' disease. However, the company is evaluating expanding its development plans, which could alter the cash runway — updated guidance is promised after key data readouts later this year. The filing also flags a new $22.8 million manufacturing commitment and adds risk factors around clinical trial data variability and delays.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMVT was trading at $39.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1B. The 52-week trading range was $14.32 to $41.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMVT - Latest Insights

IMVT
Nov 09, 2026, 7:20 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.20
Real-time Price: $33.21 info
Change: -$1.99 (-6%) info
Market Cap: $6.873B info
IMVT
Nov 09, 2026, 7:09 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.85
Real-time Price: $33.21 info
Change: -$2.64 (-7%) info
Market Cap: $6.873B info
IMVT
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.10
Real-time Price: $33.21 info
Change: +$5.11 (+18%) info
Market Cap: $6.873B info
IMVT
Nov 09, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $28.10
Real-time Price: $33.21 info
Change: +$5.11 (+18%) info
Market Cap: $6.873B info
IMVT
Sep 23, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $36.20
Real-time Price: $33.21 info
Change: -$2.99 (-8%) info
Market Cap: $6.873B info